Switzerland · Delayed Price · Currency is CHF DocMorris AG Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 10.7% year-over-year, led by 30.4% Rx and 63.1% digital services growth. Adjusted EBITDA improved by CHF 9.8 million to CHF -6.3 million, with breakeven targeted in 2026. Guidance for revenue and EBITDA is confirmed, with strong momentum in all key segments.
Fiscal Year 2025
-
Revenue grew 11.1% in 2025, driven by Rx (+33%) and digital services (+110%), with strong margin gains and a robust liquidity position. EBITDA breakeven is targeted for 2026, supported by operational efficiencies, digital expansion, and a new Google partnership.
-
Strong Rx and TeleClinic growth drove a 10.2% revenue increase in H1 2025, with gross margin up 70 bps and a solid balance sheet after a CHF 200 million capital raise. Full-year guidance is confirmed, with sequential EBITDA improvement expected as marketing spend is optimized.
-
Q1 2025 saw 13% revenue growth, with Rx up 52% and TeleClinic revenue more than doubling. A CHF 200 million capital raise is fully underwritten to fund growth, with EBITDA break-even targeted in 2026 and positive free cash flow in 2027.
Fiscal Year 2024
-
Revenue grew 7% year-over-year, with all segments contributing and non-Rx business reaching profitability. Teleclinic doubled revenues, and a CHF 200 million capital raise is planned to support Rx growth and refinance debt. Guidance will be updated post-Q1 results.
-
Breakeven achieved in the base business, with strong eRX growth following CardLink's launch and TeleClinic doubling sales. 2024 revenue is guided to grow 5–10%, with increased investment in eRX customer acquisition impacting EBITDA, but long-term profitability targets remain intact.